Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Total Debt (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Total Debt for 17 consecutive years, with $45.1 billion as the latest value for Q4 2025.

  • Quarterly Total Debt fell 9.14% to $45.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.1 billion through Dec 2025, down 9.14% year-over-year, with the annual reading at $45.1 billion for FY2025, 9.14% down from the prior year.
  • Total Debt for Q4 2025 was $45.1 billion at Bristol Myers Squibb, down from $49.0 billion in the prior quarter.
  • The five-year high for Total Debt was $55.7 billion in Q1 2024, with the low at $37.6 billion in Q3 2023.
  • Average Total Debt over 5 years is $45.0 billion, with a median of $45.0 billion recorded in 2022.
  • The sharpest move saw Total Debt decreased 15.88% in 2023, then soared 47.18% in 2024.
  • Over 5 years, Total Debt stood at $44.6 billion in 2021, then dropped by 11.75% to $39.3 billion in 2022, then grew by 1.15% to $39.8 billion in 2023, then grew by 24.83% to $49.6 billion in 2024, then decreased by 9.14% to $45.1 billion in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $45.1 billion, $49.0 billion, and $49.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.